Literature DB >> 2969292

Evidence for specific association between class I major histocompatibility antigens and the CD8 molecules of human suppressor/cytotoxic cells.

M L Blue1, K A Craig, P Anderson, K R Branton, S F Schlossman.   

Abstract

Human T lymphocytes, metabolically labeled with 35S-cysteine and 35S-methionine, were reacted with the homobifunctional cross-linking reagent, dithiobis (succinimidyl propionate) (DSP). When detergent lysates from these cells were immunoprecipitated with a monoclonal antibody reactive with the CD8 antigen, a radiolabeled protein of approximately 44 kd was coprecipitated with the CD8 molecule. Immunoprecipitates from detergent lysates prepared without prior chemical cross-linking contained only the 33 kd CD8 molecule. Similar results were obtained when T lymphocytes or a cytotoxic T cell clone (T4T8Cl) were radiolabeled with 32P-orthophosphoric acid. The 44 kd CD8-associated protein was identified as the heavy chain of the class I major histocompatibility antigen by depletion in preclearing experiments with anti-class I MHC antibody and by peptide mapping. Further analyses indicated that the CD8-class I MHC association is due, in part at least, to disulfide bonding, which may be susceptible to cleavage during processing of cell lysates.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2969292     DOI: 10.1016/0092-8674(88)90204-8

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  14 in total

1.  Short related sequences in the cytoplasmic domains of CD4 and CD8 mediate binding to the amino-terminal domain of the p56lck tyrosine protein kinase.

Authors:  A S Shaw; J Chalupny; J A Whitney; C Hammond; K E Amrein; P Kavathas; B M Sefton; J K Rose
Journal:  Mol Cell Biol       Date:  1990-05       Impact factor: 4.272

2.  Specific cleavage of the alpha 4 integrin associated with activation of peripheral T lymphocytes.

Authors:  M L Blue; G Davis; P Conrad; K Kelley
Journal:  Immunology       Date:  1993-01       Impact factor: 7.397

3.  T-cell activation. VI. Inhibitory and stimulatory effects of anti-major histocompatibility complex class I antibodies in allogeneic mixed lymphocyte culture.

Authors:  M Röpke; C Röpke; M H Claësson
Journal:  Immunology       Date:  1993-06       Impact factor: 7.397

4.  The CD4 and CD8 antigens are coupled to a protein-tyrosine kinase (p56lck) that phosphorylates the CD3 complex.

Authors:  E K Barber; J D Dasgupta; S F Schlossman; J M Trevillyan; C E Rudd
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

Review 5.  Homotypic and heterotypic in cis associations of MHC class I molecules at the cell surface.

Authors:  Fernando M Ruggiero; Sebastian Springer
Journal:  Curr Res Immunol       Date:  2022-05-23

6.  CD4 and CD8 molecules can physically associate with the same T-cell receptor.

Authors:  P F Gallagher; B Fazekas de St Groth; J F Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

7.  Circulating cytotoxic immune components in dominant Charcot-Marie-Tooth syndrome.

Authors:  L L Williams; B T Shannon; F S Wright
Journal:  J Clin Immunol       Date:  1993-11       Impact factor: 8.317

8.  Structural basis of the CD8 alpha beta/MHC class I interaction: focused recognition orients CD8 beta to a T cell proximal position.

Authors:  Rui Wang; Kannan Natarajan; David H Margulies
Journal:  J Immunol       Date:  2009-07-22       Impact factor: 5.422

9.  Intercellular adhesion molecule 1 is induced on isolated endocrine islet cells by cytokines but not by reovirus infection.

Authors:  I L Campbell; A Cutri; D Wilkinson; A W Boyd; L C Harrison
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

10.  The three-dimensional structure of a class I major histocompatibility complex molecule missing the alpha 3 domain of the heavy chain.

Authors:  E J Collins; D N Garboczi; M N Karpusas; D C Wiley
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-14       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.